Huaxi Biotech said at the 2026 semi-annual performance briefing held on October 9 that the company continues to develop R&D and industrialization around bioactive substances closely related to life and health, and gradually expand to new bioactive substances such as PDRN/PN, recombinant collagen, breast milk oligosaccharides, ergothione, and rhododendine on the basis of consolidating the traditional advantages of hyaluronic acid. Currently, some new products have entered the commercialization stage and have begun to generate revenue contributions. In terms of raw material business, new bioactive substances such as PDRN and recombinant collagen are gradually becoming new growth points.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.